Preclinical assessment of candidate analgesic drugs: Recent advances and future challenges

S. Stevens Negus, Todd W Vanderah, M. R. Brandt, E. J. Bilsky, L. Becerra, D. Borsook

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

In analgesic drug development, preclinical procedures are widely used to assess drug effects on pain-related behaviors. These procedures share two principal components: 1) a manipulation intended to produce a pain-like state in the experimental subject and 2) measurement of behaviors presumably indicative of that pain state. Drugs can then be evaluated for their ability to attenuate pain-related behaviors. In the simplest procedures, the pain state is produced by delivery of an acute noxious stimulus (e.g., a warm thermal stimulus), and the primary dependent measures focus on withdrawal responses or other nocifensive behaviors that increase in rate, frequency, or intensity in response to the noxious stimulus. This approach has been refined in two ways. First, new methods have been developed to induce more clinically relevant pain states. In particular, pain requiring clinical intervention is often associated with inflammation or neuropathy, and novel procedures have emerged to model these conditions and their ability to produce hypersensitive pain states, such as allodynia and hyperalgesia. Second, studies are incorporating a broader array of pain-related behaviors as dependent measures. For example, pain not only stimulates nocifensive behaviors but also suppresses many adaptive behaviors, such as feeding or locomotion. Measures of pain-suppressed behaviors can provide new insights into the behavioral consequences of pain and the effects of candidate analgesics. In addition, functional magnetic resonance imaging has emerged as a noninvasive tool for investigating changes in neural activity associated with pain and analgesia. Integration of these complementary approaches may improve the predictive validity of analgesic drug development.

Original languageEnglish (US)
Pages (from-to)507-514
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume319
Issue number2
DOIs
StatePublished - 2006

Fingerprint

Analgesics
Pain
Aptitude
Hyperalgesia
Psychological Adaptation
Locomotion
Pharmaceutical Preparations
Analgesia
Hot Temperature
Magnetic Resonance Imaging
Inflammation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Preclinical assessment of candidate analgesic drugs : Recent advances and future challenges. / Negus, S. Stevens; Vanderah, Todd W; Brandt, M. R.; Bilsky, E. J.; Becerra, L.; Borsook, D.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 319, No. 2, 2006, p. 507-514.

Research output: Contribution to journalArticle

Negus, S. Stevens ; Vanderah, Todd W ; Brandt, M. R. ; Bilsky, E. J. ; Becerra, L. ; Borsook, D. / Preclinical assessment of candidate analgesic drugs : Recent advances and future challenges. In: Journal of Pharmacology and Experimental Therapeutics. 2006 ; Vol. 319, No. 2. pp. 507-514.
@article{4ad5aafc120b44a8b4e23c10952308bd,
title = "Preclinical assessment of candidate analgesic drugs: Recent advances and future challenges",
abstract = "In analgesic drug development, preclinical procedures are widely used to assess drug effects on pain-related behaviors. These procedures share two principal components: 1) a manipulation intended to produce a pain-like state in the experimental subject and 2) measurement of behaviors presumably indicative of that pain state. Drugs can then be evaluated for their ability to attenuate pain-related behaviors. In the simplest procedures, the pain state is produced by delivery of an acute noxious stimulus (e.g., a warm thermal stimulus), and the primary dependent measures focus on withdrawal responses or other nocifensive behaviors that increase in rate, frequency, or intensity in response to the noxious stimulus. This approach has been refined in two ways. First, new methods have been developed to induce more clinically relevant pain states. In particular, pain requiring clinical intervention is often associated with inflammation or neuropathy, and novel procedures have emerged to model these conditions and their ability to produce hypersensitive pain states, such as allodynia and hyperalgesia. Second, studies are incorporating a broader array of pain-related behaviors as dependent measures. For example, pain not only stimulates nocifensive behaviors but also suppresses many adaptive behaviors, such as feeding or locomotion. Measures of pain-suppressed behaviors can provide new insights into the behavioral consequences of pain and the effects of candidate analgesics. In addition, functional magnetic resonance imaging has emerged as a noninvasive tool for investigating changes in neural activity associated with pain and analgesia. Integration of these complementary approaches may improve the predictive validity of analgesic drug development.",
author = "Negus, {S. Stevens} and Vanderah, {Todd W} and Brandt, {M. R.} and Bilsky, {E. J.} and L. Becerra and D. Borsook",
year = "2006",
doi = "10.1124/jpet.106.106377",
language = "English (US)",
volume = "319",
pages = "507--514",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Preclinical assessment of candidate analgesic drugs

T2 - Recent advances and future challenges

AU - Negus, S. Stevens

AU - Vanderah, Todd W

AU - Brandt, M. R.

AU - Bilsky, E. J.

AU - Becerra, L.

AU - Borsook, D.

PY - 2006

Y1 - 2006

N2 - In analgesic drug development, preclinical procedures are widely used to assess drug effects on pain-related behaviors. These procedures share two principal components: 1) a manipulation intended to produce a pain-like state in the experimental subject and 2) measurement of behaviors presumably indicative of that pain state. Drugs can then be evaluated for their ability to attenuate pain-related behaviors. In the simplest procedures, the pain state is produced by delivery of an acute noxious stimulus (e.g., a warm thermal stimulus), and the primary dependent measures focus on withdrawal responses or other nocifensive behaviors that increase in rate, frequency, or intensity in response to the noxious stimulus. This approach has been refined in two ways. First, new methods have been developed to induce more clinically relevant pain states. In particular, pain requiring clinical intervention is often associated with inflammation or neuropathy, and novel procedures have emerged to model these conditions and their ability to produce hypersensitive pain states, such as allodynia and hyperalgesia. Second, studies are incorporating a broader array of pain-related behaviors as dependent measures. For example, pain not only stimulates nocifensive behaviors but also suppresses many adaptive behaviors, such as feeding or locomotion. Measures of pain-suppressed behaviors can provide new insights into the behavioral consequences of pain and the effects of candidate analgesics. In addition, functional magnetic resonance imaging has emerged as a noninvasive tool for investigating changes in neural activity associated with pain and analgesia. Integration of these complementary approaches may improve the predictive validity of analgesic drug development.

AB - In analgesic drug development, preclinical procedures are widely used to assess drug effects on pain-related behaviors. These procedures share two principal components: 1) a manipulation intended to produce a pain-like state in the experimental subject and 2) measurement of behaviors presumably indicative of that pain state. Drugs can then be evaluated for their ability to attenuate pain-related behaviors. In the simplest procedures, the pain state is produced by delivery of an acute noxious stimulus (e.g., a warm thermal stimulus), and the primary dependent measures focus on withdrawal responses or other nocifensive behaviors that increase in rate, frequency, or intensity in response to the noxious stimulus. This approach has been refined in two ways. First, new methods have been developed to induce more clinically relevant pain states. In particular, pain requiring clinical intervention is often associated with inflammation or neuropathy, and novel procedures have emerged to model these conditions and their ability to produce hypersensitive pain states, such as allodynia and hyperalgesia. Second, studies are incorporating a broader array of pain-related behaviors as dependent measures. For example, pain not only stimulates nocifensive behaviors but also suppresses many adaptive behaviors, such as feeding or locomotion. Measures of pain-suppressed behaviors can provide new insights into the behavioral consequences of pain and the effects of candidate analgesics. In addition, functional magnetic resonance imaging has emerged as a noninvasive tool for investigating changes in neural activity associated with pain and analgesia. Integration of these complementary approaches may improve the predictive validity of analgesic drug development.

UR - http://www.scopus.com/inward/record.url?scp=33751192096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751192096&partnerID=8YFLogxK

U2 - 10.1124/jpet.106.106377

DO - 10.1124/jpet.106.106377

M3 - Article

C2 - 16751251

AN - SCOPUS:33751192096

VL - 319

SP - 507

EP - 514

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -